Research shows that certain risk factors may increase the likelihood of developing NASH. While the prospect of developing NASH may be concerning, a number of lifestyle changes may help lower the risk of developing the condition.
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug
Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib),
a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase
inhibitor (TKI) for...